Title |
Evidence for mTOR pathway activation in a spectrum of epilepsy-associated pathologies
|
---|---|
Published in |
Acta Neuropathologica Communications, July 2014
|
DOI | 10.1186/2051-5960-2-71 |
Pubmed ID | |
Authors |
Joan Liu, Cheryl Reeves, Zuzanna Michalak, Antonietta Coppola, Beate Diehl, Sanjay M Sisodiya, Maria Thom |
Abstract |
Activation of the mTOR pathway has been linked to the cytopathology and epileptogenicity of malformations, specifically Focal Cortical Dysplasia (FCD) and Tuberous Sclerosis (TSC). Experimental and clinical trials have shown than mTOR inhibitors have anti-epileptogenic effects in TS. Dysmorphic neurones and balloon cells are hallmarks of FCDIIb and TSC, but similar cells are also occasionally observed in other acquired epileptogenic pathologies, including hippocampal sclerosis (HS) and Rasmussen's encephalitis (RE). Our aim was to explore mTOR pathway activation in a range of epilepsy-associated pathologies and in lesion-negative cases. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 1 | 1% |
United States | 1 | 1% |
Ethiopia | 1 | 1% |
Unknown | 94 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 14 | 14% |
Researcher | 14 | 14% |
Student > Master | 10 | 10% |
Student > Bachelor | 10 | 10% |
Other | 6 | 6% |
Other | 20 | 21% |
Unknown | 23 | 24% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 30 | 31% |
Neuroscience | 12 | 12% |
Biochemistry, Genetics and Molecular Biology | 11 | 11% |
Agricultural and Biological Sciences | 9 | 9% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 3% |
Other | 5 | 5% |
Unknown | 27 | 28% |